CytomX Therapeutics, Inc. (CTMX)

4.5000 -0.6300 (-12.28%) 收市：04:00PM EDT

CytomX Therapeutics, Inc.

151 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 515 3185
https://www.cytomx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 120

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Sean A. McCarthy DPHIL	Chairman & CEO	1.03M	無	1967
Dr. Marcia P. Belvin Ph.D.	Senior VP & Chief Scientific Officer	634.83k	無	無
Mr. Jeffrey Landau B.S., M.B.A.	Senior VP, Head of Strategy & Chief Business Officer	580.69k	無	1979
Mr. Christopher W. Ogden	Senior VP of Finance & Accounting	無	無	1984
Mr. Lloyd A. Rowland Jr., J.D.	Senior VP, General Counsel, Chief Compliance Officer & Secretary	608.72k	無	1957
Ms. Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer	無	無	無
Ms. Leslie Robbins	Senior Vice President of Intellectual Property	無	無	無
Ms. Dawn Benson	Senior Vice President of Quality & Product Manufacturing	無	無	無
Dr. Hoyoung Huh M.D., Ph.D.	Special Advisor to Chief Executive Officer	72.5k	無	1969

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

公司管治

截至 2024年5月1日 止，CytomX Therapeutics, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：6；董事會：8；股東權利：3；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。